SCHEMBL4259537

SCHEMBL4259537

Nc1ccccc1NC(=O)c1ccc(C(=O)/C=C/c2ccc(Cl)c(Cl)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.53
HDAC1 Q13547 15/20 0.51
HDAC2 Q92769 5/20 0.51
HDAC3 O15379 5/20 0.51
MAPK1 P28482 1/20 0.51
NCOR2 Q9Y618 1/20 0.50
CYP1A1 P04798 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP1B1 Q16678 1/20 0.49
NAMPT P43490 1/20 0.48
PTGS1 P23219 1/20 0.48
HDAC4 P56524 2/20 0.47
HDAC7 Q8WUI4 2/20 0.47
HDAC10 Q969S8 2/20 0.47
HDAC11 Q96DB2 2/20 0.47
HDAC8 Q9BY41 2/20 0.47
HDAC6 Q9UBN7 2/20 0.47
HDAC9 Q9UKV0 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4259539 1.00 PTGS2 (0.53) PTGS2HDAC1HDAC2HDAC3MAPK1
SCHEMBL4258375 0.87 MAOB (0.59) PTGS2HDAC1HDAC2HDAC3MAPK1
SCHEMBL4258378 0.87 MAOB (0.59) PTGS2HDAC1HDAC2HDAC3MAPK1
SCHEMBL4261184 0.85 HDAC1 (0.68) HDAC1HDAC2HDAC3MAPK1NCOR2
SCHEMBL4261187 0.85 HDAC1 (0.68) HDAC1HDAC2HDAC3MAPK1NCOR2
SCHEMBL4256928 0.82 HDAC1 (0.55) HDAC1HDAC2HDAC3MAPK1NCOR2
SCHEMBL4256932 0.82 HDAC1 (0.55) HDAC1HDAC2HDAC3MAPK1NCOR2
SCHEMBL4255384 0.80 PTGS1 (0.74) HDAC1HDAC2HDAC3MAPK1NCOR2
SCHEMBL4255388 0.80 PTGS1 (0.74) HDAC1HDAC2HDAC3MAPK1NCOR2
SCHEMBL7030759 0.79 LMNA (0.55) PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023734-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2009-01-22 US disclosed
US-20090023734-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2009-01-22 US disclosed
US-20090023734-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2009-01-22 US disclosed
US-7282608-B2 Inhibitors of histone deacetylase METHYLGENE, INC. (CA) 2007-10-16 US disclosed
US-7282608-B2 Inhibitors of histone deacetylase METHYLGENE, INC. (CA) 2007-10-16 US disclosed
US-7282608-B2 Inhibitors of histone deacetylase METHYLGENE, INC. (CA) 2007-10-16 US disclosed
US-20060020131-A1 Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents METHYLGENE, INC. (CA) 2006-01-26 US disclosed
EP-1551795-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2005-07-13 EP disclosed
WO-2004035525-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023734-A1 INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC11, HDAC6 PTGS2 2686/4885HDAC1 1/4885HDAC2 6/4885
US-20060020131-A1 Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents HDAC1, AADAC, HDAC11 PTGS2 2183/4885HDAC1 1/4885HDAC2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.